"Care Beyond Treatment | cCARE serves the greater San Diego and Fresno communities. Our mission is to provide quality and value in cancer treatment, hematology and other patient health services through a network of doctors and providers who are focused on outcomes, research and personalized care. This includes screening, diagnosing and treating breast, lung, prostate, bladder, ovarian and other cancers."

During the past decade, California Cancer Associates for Research and Excellence conducted 32 clinical trials. In the 10-year time frame, 32 clinical trials started and 39 clinical trials were completed, i.e. on average, 121.9% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 16 clinical trials were completed. i.e. 114.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "California Cancer Associates for Research and Excellence" #1 sponsor was "Oncotherapeutics" with 6 trials, followed by "Hoffmann-La Roche" with 5 trials sponsored, "Celgene" with 4 trials sponsored, "Eli Lilly and Company" with 4 trials sponsored and "Genentech, Inc." with 4 trials sponsored. Other sponsors include 53 different institutions and companies that sponsored additional 44 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "California Cancer Associates for Research and Excellence" #1 collaborator was "National Cancer Institute (NCI)" with 6 trials as a collaborator, "Cancer and Leukemia Group B" with 4 trials as a collaborator, "North Central Cancer Treatment Group" with 3 trials as a collaborator, "Celgene Corporation" with 2 trials as a collaborator and "Eastern Cooperative Oncology Group" with 2 trials as a collaborator. Other collaborators include 17 different institutions and companies that were collaborators in the rest 24 trials.

According to Clinical.Site data, the most researched conditions in "California Cancer Associates for Research and Excellence" are "Breast Cancer" (12 trials), "Multiple Myeloma" (10 trials), "Colorectal Cancer" (6 trials), "Metastatic Breast Cancer" (4 trials) and "Pancreatic Cancer" (4 trials). Many other conditions were trialed in "California Cancer Associates for Research and Excellence" in a lesser frequency.

Most popular intervention types in "California Cancer Associates for Research and Excellence" are "Drug" (76 trials), "Biological" (10 trials), "Other" (6 trials), "Radiation" (2 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Dexamethasone" (8 trials), "Cyclophosphamide" (7 trials), "Lenalidomide" (6 trials) and "Paclitaxel" (6 trials). Other intervention names were less common.

The vast majority of trials in "California Cancer Associates for Research and Excellence" are 68 trials for "All" genders, 10 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "California Cancer Associates for Research and Excellence". undefined are not yet recruiting, 9 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 37 completed trials in California Cancer Associates for Research and Excellence, 1 suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in California Cancer Associates for Research and Excellence, 24 "Phase 1" clinical trials were conducted, 31 "Phase 2" clinical trials and 35 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".

California Cancer Associates for Research and Excellence has several departments that took part in Clinical trials: "California Cancer Associates for Research & Excellence, Inc." - 11 trials